OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

@article{Tournigand2006OPTIMOX1AR,
  title={OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.},
  author={Christophe Tournigand and Andr{\'e}s Cervantes and Ari{\'e} Figer and G{\'e}rard Lledo and Michel Flesch and Marc Buyse and Laurent Mineur and Elisabeth Carola and P. L. Etienne and F Rivera and Isabel Chirivella and Nathalie Perez-Staub and Christophe Louvet and Thierry Andr{\'e} and Isabelle Tabah-Fisch and Aimery de Gramont},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 3},
  pages={394-400}
}
PURPOSE In metastatic colorectal cancer, a combination of leucovorin (LV) and fluorouracil (FU) with oxaliplatin (FOLFOX) 4 is a standard first-line regimen. The cumulative neurotoxicity of oxaliplatin often requires therapy to be stopped in patients who are still responding. This study evaluates a new strategy of intermittent oxaliplatin treatment that is based on FOLFOX7, a simplified leucovorin and fluorouracil regimen with high-dose oxaliplatin. PATIENTS AND METHODS Previously untreated… CONTINUE READING
Highly Influential
This paper has highly influenced 16 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 233 extracted citations

Expert consensus on maintenance treatment for metastatic colorectal cancer in China

Chinese journal of cancer • 2016
View 7 Excerpts
Highly Influenced

Bevacizumab in the therapy for refractory metastatic colorectal cancer

Biologics : targets & therapy • 2008
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…